Analytical Data
-
Gene name
SPTbN4
- Application
-
Alternative Names
QV; SPNB4; SPTBN3; Beta-IV spectrin; Spectrin, non-erythroid beta chain 3
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H254
-
Expression Region
Lys64~Ser285
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SPTbN4, a member of the Splicing Protein family, has garnered significant interest in recent years due to its critical role in RNA splicing and post-transcriptional regulation. Aberrations in splicing mechanisms are implicated in various diseases, including cancer and neurodegenerative disorders, making the study of splicing proteins and their functional properties crucial for understanding disease pathology. SPTbN4, specifically, has been linked to the modulation of gene expression and the maintenance of cellular homeostasis, highlighting its potential as a therapeutic target. Recent advancements in recombinant protein technology have enabled the production and characterization of SPTbN4, facilitating in-depth studies of its structure, function, and interaction with other cellular components. Researchers are particularly focused on elucidating the molecular mechanisms by which SPTbN4 influences splicing dynamics and gene regulation, which could provide novel insights into the development of targeted therapies for splicing-related diseases. Understanding the specific roles of SPTbN4 in splicing processes could lead to innovative approaches in drug development and personalized medicine, ultimately contributing to improved treatment outcomes.
